Journal Report

Nature Reviews Clinical Oncology

Download PDF
Journal Information
Journal Title
Nature Reviews Clinical Oncology
Publisher
Nature Publishing Group
ISSN
1759-4774
E-ISSN
1759-4782
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma
Dania Cioni, Ezequiel Mauro, Dan Feng et al.
2026-10-28
DOI: 10.1038/s41571-026-01210-6
Problematic control arms in National Cancer Institute myeloma trials
Jacqueline Kunesh, Ghulam Rehman Mohyuddin
2026-10-28
DOI: 10.1038/s41571-026-01221-3
No cancer research without older adults, from prevention to end of life: a manifesto
Sophie Pilleron, Enrique Soto-Perez-de-Celis, Nicolò Matteo Luca Battisti
2026-10-20
DOI: 10.1038/s41571-026-01220-4
An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
Vivek Subbiah, Razelle Kurzrock
2026-10-13
DOI: 10.1038/s41571-026-01216-0
A modular framework for antibody–drug conjugate biomarkers
Jia Liu, Dan-Yun Ruan, Nicholas McNamee et al.
2026-10-9
DOI: 10.1038/s41571-026-01213-3
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
Paolo Tarantino, Carmine Valenza, Elia Segui et al.
2026-10-8
DOI: 10.1038/s41571-026-01211-5
Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma
Peter Sidaway
2026-10-8
DOI: 10.1038/s41571-026-01215-1
Exercise therapy in cancer prevention and treatment
Joshua W. Bliss, Lee W. Jones
2026-10-7 Vol. 23 Issue 11 Pages 872-892
DOI: 10.1038/s41571-026-01201-7
Exploring the immunological effects of antibody–drug conjugates
Paola Zagami, Dario Trapani, Antonio Marra et al.
2026-10-6
DOI: 10.1038/s41571-026-01209-z
Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL
Diana Romero
2026-10-1
DOI: 10.1038/s41571-026-01214-2
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 31, 2026 13:36